Pharmaceutical versions of GLP-1 are designed to mimic this natural hormone but last longer in the body, giving patients the metabolic benefits without the need for constant production
This method of administration, combined with lifestyle support, helps clients achieve gradual, sustainable weight loss
This apparent selectivity may allow Ipamorelin to potentially stimulate growth hormone release by pituitary cells without necessarily triggering the release of cortisol or adrenocorticotropic hormone (ACTH)
PlexusDx's Precision Peptide Genetic Test maps 150+ insights across FTO and MC4R, and 46 other peptides to reveal your metabolic response profile
Semaglutide is a GLP-1 receptor agonist that was originally developed for patients with Type 2 diabetes, but when providers and pharmaceutical developers noticed how much weight their patients were losing, they began to study semaglutide exclusively for weight loss
MC3R, which appears to be primarily expressed in the brain, especially within the hypothalamus, might play a role in energy homeostasis